{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:09:14Z","timestamp":1788728954141,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmorw.2025.100155","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:15:01Z","timestamp":1748938501000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study"],"prefix":"10.1016","volume":"9","author":[{"given":"P.","family":"Barthelemy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Auberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Malak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Samia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Texier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmorw.2025.100155_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmorw.2025.100155_bib2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100155_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100155_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.17.2.253","article-title":"Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.esmorw.2025.100155_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.esmorw.2025.100155_bib6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100155_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40265-014-0243-3","article-title":"Pazopanib: a review of its use in the management of advanced renal cell carcinoma","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100155_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11523-017-0511-8","article-title":"Pazopanib: a review in advanced renal cell carcinoma","volume":"12","author":"Frampton","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmorw.2025.100155_bib9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Eng J Med"},{"issue":"18","key":"10.1016\/j.esmorw.2025.100155_bib10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmorw.2025.100155_bib11","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100155_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdv601","article-title":"Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study","volume":"27","author":"Perez-Valderrama","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100155_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1634\/theoncologist.2018-0787","article-title":"PRINCIPAL Study Group. Prospective observational study of pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL study)","volume":"24","author":"Schmidinger","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100155_bib14","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clgc.2019.01.018","article-title":"Real-world effectiveness and safety of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma","volume":"17","author":"Procopio","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100155_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11864-019-0638-1","article-title":"The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions","volume":"20","author":"Salgia","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.esmorw.2025.100155_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100155_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100155_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100155_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","article-title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100155_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jcpt.13282","article-title":"A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma","volume":"46","author":"Heo","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100155_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/OP.22.00660","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO Guideline Q&A","volume":"19","author":"Singer","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100155_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100155_bib25","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100155_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib27","article-title":"First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"5","author":"Aldin","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.clgc.2022.06.012","article-title":"A study of pazopanib safety and efficacy in patients with advanced clear cell renal cell carcinoma and ECOG performance status 2 (Pazo2): an open label, multicentre, single arm, phase II trial","volume":"20","author":"Zarkar","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100155_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clgc.2024.01.006","article-title":"Impact of metastatic site in favorable-risk renal cell carcinoma receiving sunitinib or pazopanib","volume":"22","author":"Catalano","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14737140.2023.2200168","article-title":"Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?","volume":"23","author":"Corian\u00f2","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmorw.2025.100155_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102971","article-title":"Systemic therapy in metastatic renal cell carcinoma: emerging challenges in therapeutic choice","volume":"152","author":"Parmar","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"10.1016\/j.esmorw.2025.100155_bib32","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.3390\/cancers14225486","article-title":"The non-interventional PAZOREAL study to assess the effectiveness and safety of pazopanib in a real-life setting: reflecting a changing mRCC treatment landscape","volume":"14","author":"Doehn","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100155_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1186\/s12885-021-08738-z","article-title":"Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study","volume":"21","author":"Erman","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmorw.2025.100155_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803935","article-title":"Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in The Netherlands","volume":"13","author":"van Laar","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100155_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40273-018-0746-y","article-title":"Economic burden of renal cell carcinoma-part I: an updated review","volume":"37","author":"Chien","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.esmorw.2025.100155_bib37","article-title":"Cost-effectiveness of the first line treatment options for metastatic renal cell carcinoma in India","volume":"9","author":"Gupta","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100155_bib38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294982012500044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294982012500044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:18:12Z","timestamp":1788725892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294982012500044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S294982012500044X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100155","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}